Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
PLoS One. 2018 Jun 12;13(6):e0198456. doi: 10.1371/journal.pone.0198456. eCollection 2018.
The Kidney Failure Risk Equation (KFRE) predicts the need for dialysis or transplantation using age, sex, estimated glomerular filtration rate (eGFR), and urine albumin to creatinine ratio (ACR). The eGFR and ACR have known biological and analytical variability. We examined the effect of biological and analytical variability of eGFR and ACR on the 2-year KFRE predicted kidney failure probabilities using single measure and the average of repeat measures of simulated eGFR and ACR. Previously reported values for coefficient of variation (CV) for ACR and eGFR were used to calculate day to day variability. Variation was also examined with outpatient laboratory data from patients with an eGFR between 15 and 50 mL/min/1.72 m2. A web application was developed to calculate and model day to day variation in risk. The biological and analytical variability related to ACR and eGFR lead to variation in the predicted probability of kidney failure. A male patient age 50, ACR 30 mg/mmol and eGFR 25, had a day to day variation in risk of 7% (KFRE point estimate: 17%, variability range 14% to 21%). The addition of inter laboratory variation due to different instrumentation increased the variability to 9% (KFRE point estimate 17%, variability range 13% to 22%). Averaging of repeated measures of eGFR and ACR significantly decreased the variability (KFRE point estimate 17%, variability range 15% to 19%). These findings were consistent when using outpatient laboratory data which showed that most patients had a KFRE 2-year risk variability of ≤ 5% (79% of patients). Approximately 13% of patients had variability from 5-10% and 8% had variability > 10%. The mean age (SD) of this cohort was 64 (15) years, 36% were females, the mean (SD) eGFR was 32 (10) ml/min/1.73m2 and median (IQR) ACR was 22.7 (110). Biological and analytical variation intrinsic to the eGFR and ACR may lead to a substantial degree of variability that decreases with repeat measures. Use of a web application may help physicians and patients understand individual patient's risk variability and communicate risk (https://mccudden.shinyapps.io/kfre_app/). The web application allows the user to alter age, gender, eGFR, ACR, CV (for both eGFR and ACR) as well as units of measurements for ACR (g/mol versus mg/g).
肾衰竭风险方程(KFRE)使用年龄、性别、估算肾小球滤过率(eGFR)和尿白蛋白与肌酐比值(ACR)预测透析或移植的需求。eGFR 和 ACR 存在已知的生物学和分析变异性。我们使用模拟 eGFR 和 ACR 的单次测量和重复测量的平均值来研究 eGFR 和 ACR 的生物学和分析变异性对 2 年 KFRE 预测肾衰竭概率的影响。先前报告的 ACR 和 eGFR 的变异系数(CV)值用于计算日常变异性。还使用 15 至 50 mL/min/1.72 m2 之间 eGFR 的门诊患者的实验室数据检查了变异性。开发了一个网络应用程序来计算和模拟风险的日常变化。与 ACR 和 eGFR 相关的生物学和分析变异性导致肾衰竭预测概率的变化。一名 50 岁的男性患者,ACR 为 30 mg/mmol,eGFR 为 25,风险的日常变化为 7%(KFRE 点估计值:17%,变异性范围为 14%至 21%)。由于不同仪器导致的实验室间差异增加了 9%的变异性(KFRE 点估计值 17%,变异性范围 13%至 22%)。eGFR 和 ACR 重复测量的平均值显著降低了变异性(KFRE 点估计值 17%,变异性范围 15%至 19%)。当使用门诊实验室数据时,这些发现是一致的,这些数据显示大多数患者的 KFRE 2 年风险变异性≤5%(79%的患者)。约 13%的患者的变异性在 5-10%之间,8%的患者的变异性>10%。该队列的平均年龄(SD)为 64(15)岁,36%为女性,平均(SD)eGFR 为 32(10)ml/min/1.73m2,中位数(IQR)ACR 为 22.7(110)。eGFR 和 ACR 固有的生物学和分析变异性可能导致相当大的变异性,这种变异性随着重复测量而降低。使用网络应用程序可能有助于医生和患者了解个体患者的风险变异性并传达风险(https://mccudden.shinyapps.io/kfre_app/)。该网络应用程序允许用户更改年龄、性别、eGFR、ACR、CV(eGFR 和 ACR 两者)以及 ACR 的测量单位(g/mol 与 mg/g)。